Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11394808 | 0.78 | TSHR (0.50) | TSHRRECQLHTTMAPTHPGD | |
| SCHEMBL17073 | 0.76 | TSHR (0.48) | TSHRRECQLHTTMAPTHPGD | |
| SCHEMBL1164361 | 0.76 | HTT (0.50) | TSHRRECQLHTTMAPTHPGD | |
| SCHEMBL30183177 | 0.76 | TSHR (0.40) | TSHRRECQLHTTMAPTHPGD | |
| SCHEMBL2634202 | 0.76 | TSHR (0.48) | TSHRRECQLHTTMAPTHPGD | |
| SCHEMBL25351023 | 0.76 | TSHR (0.44) | TSHRRECQLHTTMAPTHPGD | |
| SCHEMBL11400978 | 0.76 | HPGD (0.54) | TSHRHTTMAPTHPGDALDH1A1 | |
| SCHEMBL4802533 | 0.75 | CA2 (0.53) | CA2RAB9A | |
| SCHEMBL10536613 | 0.74 | TSHR (0.47) | TSHRRECQLHTTMAPTHPGD | |
| SCHEMBL10536301 | 0.74 | TSHR (0.47) | TSHRRECQLHTTMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528773-A | N-alkylation method of sulfonamide compound | 赣南医科大学 | 2025-02-28 | — | — | CN | claimed |
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | claimed |
| CN-107541015-A | A kind of preparation method of CNT montmorillonite self-assembled nanometer powder flexibilizing epoxy composite | 河海大学 | 2018-01-05 | — | — | CN | claimed |
| CN-107523015-A | CNT montmorillonite self-assembled nanometer powder is grafted the preparation method of galss fiber reinforced resin composite | 河海大学 | 2017-12-29 | — | — | CN | claimed |
| CN-107445142-A | A kind of preparation method of CNT montmorillonite self-assembled nanometer powder | 河海大学 | 2017-12-08 | — | — | CN | claimed |
| CN-101516837-A | Sulfonamide derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | CN | claimed |
| CN-101163468-A | Novel combination of sulfonamide compounds | EISAI R&D MAN CO LTD (JP) | 2008-04-16 | — | — | CN | claimed |
| US-12552757-B2 | NRF2-activating compound | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2026-02-17 | — | — | US | disclosed |
| EP-4573088-A1 | HETEROCYCLE RBM39 MODULATORS | Recursion Pharmaceuticals, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-119630658-A | Heterocyclic RBM39 modulators | 递归医药公司 | 2025-03-14 | — | — | CN | disclosed |
| US-12247004-B2 | 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | Oxford Drug Design Limited (GB) | 2025-03-11 | — | — | US | disclosed |
| CN-114206335-B | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119528773-A | N-alkylation method of sulfonamide compound | 赣南医科大学 | 2025-02-28 | — | — | CN | disclosed |
| EP-0182691-B1 | SUBSTITUTED THIOPHENE-2-SULFONAMIDES AND THEIR PREPARATION | MERCK & CO. INC. (US) | 1990-07-04 | — | — | EP | disclosed |
| US-4847289-A | Thiophene sulfonamide antiglaucoma agents | MERCK & CO., INC. (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0295049-A2 | Thiophene sulfonamide antiglaucoma agents | MERCK & CO. INC. (US) | 1988-12-14 | — | — | EP | disclosed |
| US-4721794-A | Substituted thiophene-2-sulfonamide antiglaucoma agents | MERCK & CO., INC. (US) | 1988-01-26 | — | — | US | disclosed |
| EP-0182691-A1 | Substituted thiophene-2-sulfonamides and their preparation | MERCK & CO. INC. (US) | 1986-05-28 | — | — | EP | disclosed |
| EP-0042731-B1 | LARVICIDES, INSECTICIDES, ACARICIDES AND MITICIDES, PROCESSES FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM | Pfizer Limited (GB) | 1984-12-05 | — | — | EP | disclosed |
| EP-0042731-A1 | Larvicides, insecticides, acaricides and miticides, processes for preparing them and compositions containing them | Pfizer Limited (GB) | 1981-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247004-B2 | 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | AARS1, ASNS, GARS1 | TSHR 2064/4885RECQL 1655/4885CA2 2761/4885 |
| US-12552757-B2 | NRF2-activating compound | NFE2L2, NFE2, KEAP1 | TSHR 2086/4885RECQL 3611/4885CA2 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.